clinical trial · NCT06152042
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
Type 1 Diabetes MellitusBMF-219
brief summary
Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.
started
Dec 28, 2023
primary completion
May 20, 2025
completion
Jul 18, 2025
last updated
May 14, 2026
detailed description
Study COVALENT-112 is a 52-week, Phase 2 trial designed to examine beta-cell function, insulin sensitivity, and both glucose and lipid metabolism in participants with T1D treated with BMF-219. BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
official title
Phase 2 Randomized, Double-blind Trial of BMF-219 Compared to Placebo in Participants With Type 1 Diabetes Mellitus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol